비교리스트

 카트 문의
시장보고서
상품코드
1424054

세계 시토메갈로바이러스 치료 시장 - 점유율, 시장 규모, 동향, 산업 분석 보고서 : 약제별, 용도별, 유통 채널별, 지역별 부문 예측(2024-2032년)

Cytomegalovirus Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug (Ganciclovir, Valganciclovir, Cidofovir, Foscarnet, Others); By Application; By Distribution Channel; By Region; Segment Forecast, 2024- 2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 115 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최근 조사에 따르면, 시토메갈로바이러스 치료 세계 시장 규모는 2032년까지 10억 3,516만 달러에 달할 전망입니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.

혁신적인 치료 접근법은 시토메갈로바이러스(CMV) 치료 시장의 강력한 성장을 가속합니다. 항바이러스제물 개발, 면역요법 및 표적 치료에 대한 새로운 전략으로 시장이 변모하고 있습니다. 입양 T 세포 이식 및 면역조절제는 CMV 감염에 대한 면역 반응을 증가시킬 수 있는 것으로 인식되고 있습니다. 첨단 약물 제제와 병용 요법에 대한 지속적인 조사를 통해 더욱 효과적이고 표적화된 옵션이 탄생하고 있습니다. CMV 치료 시장은 선진적이고 환자 중심 솔루션에 대한 수요에 적응하고 있으며, 시토메갈로바이러스 감염과 관련된 복잡한 문제를 해결하기 위해 과학적 진보와 치료 혁신의 시너지 효과를 보여줍니다.

CMV 감염이 공중 보건에 미치는 영향을 인식하고, 각국 정부는 연구, 진단 및 고급 치료 솔루션에 적극적으로 자금을 할당하고 있습니다. 이러한 전략적 노력은 인지도 향상, 조기 발견 확보, 최첨단 치료 접근을 촉진하는 데 중점을 둡니다. 특히 간시클로비르와 같은 항바이러스제의 연구개발에 대한 재정지원은 CMV 치료의 수준을 높이고 있습니다. 또한 정부 주도 프로그램은 사회적 약자의 특정 과제를 대상으로 하며 CMV 치료의 협력적인 진보를 촉진하고 보다 광범위한 세계 공중 보건 목표에 기여하고 있습니다.

핵산 증폭 분석 및 혈청학적 검사와 같은 정밀하고 신속한 도구는 조기 및 정확한 CMV 검출을 가능하게 하며, 간시클로비르와 같은 치료에 대한 수요를 촉진합니다. 포인트 오브 케어 검사와 고급 영상 진단법은 진단 능력을 더욱 향상시키고 시기 적절한 CMV 식별을 위한 새로운 길을 열어줍니다. 첨단 진단 및 치료법의 시너지 효과로 환자 관리를 재구성하고 맞춤 치료 접근법을 제공합니다. 기술 진화가 진행됨에 따라 CMV 치료 시장은 성장 기회가 확대되고 환자의 결과를 향상시키는 데 혁신이 중요한 역할을합니다.

개인화된 건강 관리로의 전환은 치료 계획을 개별 요구에 맞게 조정하고, 어드히어런스를 높이고, CMV 감염의 복잡성을 해결합니다. 혁신적인 치료법은 부작용을 최소화하고 치료 성적을 개선하는 것을 최우선으로 하고, 환자 친화적인 투여법과 병용 요법은 CMV 치료의 진화에 기여하고 있습니다. 환자 중심의 의료 동향과 함께이 시장은 시토메갈로바이러스 감염 치료의 진보와 최적화를 위해 유망합니다.

시토메갈로바이러스 치료 시장 보고서 하이라이트

2023년에는 항바이러스 효과, 바이러스의 선택적 표적화, 임상적 효능으로 간시클로비르 부문이 큰 시장 점유율을 차지했습니다.

2023년에는 CMV 재활성화 위험 증가와 전반적인 결과 개선의 필요성으로 줄기세포 이식 분야가 큰 시장 점유율을 차지했습니다.

2023년, 병원 약국 부문은 환자의 지속적인 진단 및 모니터링, 건강 관리 유닛 내 접근성의 용이성으로 인해 큰 수익 점유율을 차지했습니다.

2023년에는 북미가 CMV 감염의 유행과 발생률, 연구개발에 의해 세계 시장을 독점했습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 시토메갈로바이러스 치료 시장 인사이트

  • 시토메갈로바이러스 치료 시장 - 유통 채널의 스냅샷
  • 시토메갈로바이러스 치료 시장 역학
    • 성장 촉진요인과 기회
      • 시토메갈로바이러스 감염의 발생률 증가로 제품 수요가 자극될 것으로 예측
      • 이식 활동 증가에 의해 시토메갈로바이러스 치료 시장의 성장이 기대됨
    • 억제요인과 과제
      • 고액의 치료비가 시장 성장을 방해할 가능성이 있다
  • PESTEL 분석
  • 시토메갈로바이러스 치료 시장 유통 채널의 동향
  • 밸류체인 분석
  • COVID-19 감염의 영향 분석

제5장 세계의 시토메갈로바이러스 치료 시장, 약제별

  • 주요 조사 결과
  • 소개
  • 간사이클로비어
  • 발간사이클로비어
  • 시드포비르
  • 포스카넷
  • 기타

제6장 세계의 시토메갈로바이러스 치료 시장, 용도별

  • 주요 조사 결과
  • 소개
  • 장기 이식
  • 줄기세포 이식
  • 선천성 CMV 감염증
  • 기타

제7장 세계의 시토메갈로바이러스 치료 시장, 유통 채널별

  • 주요 조사 결과
  • 소개
  • 병원 약국
  • 소매 약국
  • 기타

제8장 세계의 시토메갈로바이러스 치료 시장, 지역별

  • 주요 조사 결과
  • 소개
    • 시토메갈로바이러스 치료 시장 평가, 지역별(2019-2032년)
  • 시토메갈로바이러스 치료 시장 - 북미
    • 북미 : 시토메갈로바이러스 치료 시장, 약제별(2019-2032년)
    • 북미 : 시토메갈로바이러스 치료 시장, 유통 채널별(2019-2032년)
    • 북미 : 시토메갈로바이러스 치료 시장, 용도별(2019-2032년)
    • 시토메갈로바이러스 치료 시장 - 미국
    • 시토메갈로바이러스 치료 시장 - 캐나다
  • 시토메갈로바이러스 치료 시장 - 유럽
    • 유럽 : 시토메갈로바이러스 치료 시장, 약제별(2019-2032년)
    • 유럽 : 시토메갈로바이러스 치료 시장, 유통 채널별(2019-2032년)
    • 유럽 : 시토메갈로바이러스 치료 시장, 용도별(2019-2032년)
    • 시토메갈로바이러스 치료 시장 - 영국
    • 시토메갈로바이러스 치료 시장 - 프랑스
    • 시토메갈로바이러스 치료 시장 - 독일
    • 시토메갈로바이러스 치료 시장 - 이탈리아
    • 시토메갈로바이러스 치료 시장 - 스페인
    • 시토메갈로바이러스 치료 시장 - 네덜란드
    • 시토메갈로바이러스 치료 시장 - 러시아
  • 시토메갈로바이러스 치료 시장 - 아시아태평양
    • 아시아태평양 : 시토메갈로바이러스 치료 시장, 약제별(2019-2032년)
    • 아시아태평양 : 시토메갈로바이러스 치료 시장, 유통 채널별(2019-2032년)
    • 아시아태평양 : 시토메갈로바이러스 치료 시장, 용도별(2019-2032년)
    • 시토메갈로바이러스 치료 시장 - 중국
    • 시토메갈로바이러스 치료 시장 - 인도
    • 시토메갈로바이러스 치료 시장 - 말레이시아
    • 시토메갈로바이러스 치료 시장 - 일본
    • 시토메갈로바이러스 치료 시장 - 인도네시아
    • 시토메갈로바이러스 치료 시장 - 한국
  • 시토메갈로바이러스 치료 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 시토메갈로바이러스 치료 시장, 약제별(2019-2032년)
    • 중동 및 아프리카 : 시토메갈로바이러스 치료 시장, 유통 채널별(2019-2032년)
    • 중동 및 아프리카 : 시토메갈로바이러스 치료 시장, 용도별(2019-2032년)
    • 시토메갈로바이러스 치료 시장 - 사우디아라비아
    • 시토메갈로바이러스 치료 시장 - 아랍에미리트(UAE)
    • 시토메갈로바이러스 치료 시장 - 이스라엘
    • 시토메갈로바이러스 치료 시장 - 남아프리카
  • 시토메갈로바이러스 치료 시장 - 라틴아메리카
    • 라틴아메리카 : 시토메갈로바이러스 치료 시장, 약제별(2019-2032년)
    • 라틴아메리카 : 시토메갈로바이러스 치료 시장, 유통 채널별(2019-2032년)
    • 라틴아메리카 : 시토메갈로바이러스 치료 시장, 용도별(2019-2032년)
    • 시토메갈로바이러스 치료 시장 - 멕시코
    • 시토메갈로바이러스 치료 시장 - 브라질
    • 시토메갈로바이러스 치료 시장 - 아르헨티나

제9장 경쟁 구도

  • 확장 및 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 프로파일

  • Bayer AG
  • Bristol Myers Squibb
  • Chimerix
  • Clinigen Group
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi
  • Genentech, Inc.
  • Gilead Sciences, Inc
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific
JHS 24.02.28

The global Cytomegalovirus Treatment market size is expected to reach USD 1,035.16 million by 2032, according to a new study by Polaris Market Research. The report "Cytomegalovirus Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug (Ganciclovir, Valganciclovir, Cidofovir, Foscarnet, Others); By Application; By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Innovative therapeutic approaches are propelling robust growth in the Cytomegalovirus (CMV) Treatment Market. The market is transforming with novel strategies in antiviral drug development, immunotherapies, and targeted treatments. Adoptive T-cell transfer and immune modulators are gaining recognition for their potential to boost immune responses against CMV infections. Ongoing research into advanced drug formulations and combination therapies is generating more effective and targeted options. The CMV treatment market is adapting to the demand for advanced and patient-centric solutions, showcasing the synergy between scientific advancements and therapeutic innovation in addressing complexities associated with cytomegalovirus infections.

Recognizing the public health impact of CMV infections, governments globally are actively allocating funds for research, diagnosis, and advanced treatment solutions. These strategic efforts focus on increasing awareness, ensuring early detection, and promoting accessibility to cutting-edge therapies. Financial support for research and development, particularly in antiviral drugs like Ganciclovir, elevates the standard of CMV treatment. Government-led programs also target specific challenges in vulnerable populations, fostering collaborative advancements in the CMV treatment landscape and contributing to broader global public health goals.

Precise and rapid tools like nucleic acid amplification assays and serological tests enable early and accurate CMV detection, driving demand for treatments such as Ganciclovir. Point-of-care testing and sophisticated imaging modalities further enhance diagnostic capabilities, opening new avenues for timely CMV identification. The synergy between advanced diagnostics and treatment modalities reshapes patient care, offering personalized therapeutic approaches. With ongoing technological evolution, the CMV treatment market is set to witness expanded growth opportunities, emphasizing the central role of innovation in enhancing overall patient outcomes.

The shift towards personalized healthcare tailors treatment plans to individual needs, enhancing adherence and addressing CMV infection complexities. Innovative therapies prioritize minimizing side effects and improving outcomes, while patient-friendly administration methods and combination therapies contribute to the evolving CMV treatment landscape. Aligned with the trend of patient-centric care, the market holds promise for advancing and optimizing treatments for cytomegalovirus infections.

Cytomegalovirus Treatment Market Report Highlights

In 2023, the ganciclovir segment accounted for significant market share owing to antiviral efficacy, selective viral targeting, and clinical effectiveness.

In 2023, the stem cell transplantation segment accounted for significant market share owing to elevated risk of CMV reactivation and need for improving overall outcomes.

In 2023, the hospital pharmacy segment held significant revenue share owing to continuous diagnosis and monitoring of patients, and ease of access within healthcare units.

In 2023, North America region dominated the global market due to prevalence and incidence of CMV infections, and research and development.

The market is highly competitive owing to the existence of market players with a global presence, including Clinigen Group, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Takeda Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. among others.

Polaris Market Research has segmented the Cytomegalovirus Treatment market report based on drug, application, distribution channel, and region:

Cytomegalovirus Treatment, Drug Outlook (Revenue - USD Million, 2019 - 2032)

  • Ganciclovir
  • Valganciclovir
  • Cidofovir
  • Foscarnet
  • Others

Cytomegalovirus Treatment, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Organ Transplantation
  • Stem Cell Transplantation
  • Congenital CMV Infection
  • Others

Cytomegalovirus Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Cytomegalovirus Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cytomegalovirus Treatment Market Insights

  • 4.1. Cytomegalovirus Treatment Market - Distribution Channel Snapshot
  • 4.2. Cytomegalovirus Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of cytomegalovirus infections is projected to spur the product demand
      • 4.2.1.2. Rising transplantation activities is expected to drive cytomegalovirus treatment market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Cytomegalovirus Treatment Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Cytomegalovirus Treatment Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
  • 5.3. Ganciclovir
    • 5.3.1. Global Cytomegalovirus Treatment Market, by Ganciclovir, by Region, 2019-2032 (USD Million)
  • 5.4. Valganciclovir
    • 5.4.1. Global Cytomegalovirus Treatment Market, by Valganciclovir, by Region, 2019-2032 (USD Million)
  • 5.5. Cidofovir
    • 5.5.1. Global Cytomegalovirus Treatment Market, by Cidofovir, by Region, 2019-2032 (USD Million)
  • 5.6. Foscarnet
    • 5.6.1. Global Cytomegalovirus Treatment Market, by Foscarnet, by Region, 2019-2032 (USD Million)
  • 5.7. Others
    • 5.7.1. Global Cytomegalovirus Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Cytomegalovirus Treatment Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 6.3. Organ Transplantation
    • 6.3.1. Global Cytomegalovirus Treatment Market, by Organ Transplantation, by Region, 2019-2032 (USD Million)
  • 6.4. Stem Cell Transplantation
    • 6.4.1. Global Cytomegalovirus Treatment Market, by Stem Cell Transplantation, by Region, 2019-2032 (USD Million)
  • 6.5. Congenital CMV Infection
    • 6.5.1. Global Cytomegalovirus Treatment Market, by Congenital CMV Infection, by Region, 2019-2032 (USD Million)
  • 6.6. Others
    • 6.6.1. Global Cytomegalovirus Treatment Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Cytomegalovirus Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Global Cytomegalovirus Treatment Market, by Hospital Pharmacy, By Region, 2019-2032 (USD Million)
  • 7.4. Retail Pharmacy
    • 7.4.1. Global Cytomegalovirus Treatment Market, by Retail Pharmacy, By Region, 2019-2032 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Cytomegalovirus Treatment Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Cytomegalovirus Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Cytomegalovirus Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Cytomegalovirus Treatment Market - North America
    • 8.3.1. North America: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.3.2. North America: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.3. North America: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.3.4. Cytomegalovirus Treatment Market - U.S.
      • 8.3.4.1. U.S.: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.3.5. Cytomegalovirus Treatment Market - Canada
      • 8.3.5.1. Canada: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.4. Cytomegalovirus Treatment Market - Europe
    • 8.4.1. Europe: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.3. Europe: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.4.4. Cytomegalovirus Treatment Market - UK
      • 8.4.4.1. UK: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.4.5. Cytomegalovirus Treatment Market - France
      • 8.4.5.1. France: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.5.3. France: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.4.6. Cytomegalovirus Treatment Market - Germany
      • 8.4.6.1. Germany: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.4.7. Cytomegalovirus Treatment Market - Italy
      • 8.4.7.1. Italy: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.4.8. Cytomegalovirus Treatment Market - Spain
      • 8.4.8.1. Spain: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.4.9. Cytomegalovirus Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.4.10. Cytomegalovirus Treatment Market - Russia
      • 8.4.10.1. Russia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.5. Cytomegalovirus Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.5.4. Cytomegalovirus Treatment Market - China
      • 8.5.4.1. China: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.4.3. China: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.5.5. Cytomegalovirus Treatment Market - India
      • 8.5.5.1. India: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.5.3. India: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.5.6. Cytomegalovirus Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.5.7. Cytomegalovirus Treatment Market - Japan
      • 8.5.7.1. Japan: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.5.8. Cytomegalovirus Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.5.9. Cytomegalovirus Treatment Market - South Korea
      • 8.5.9.1. South Korea: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.6. Cytomegalovirus Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.6.4. Cytomegalovirus Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.6.5. Cytomegalovirus Treatment Market - UAE
      • 8.6.5.1. UAE: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.6.6. Cytomegalovirus Treatment Market - Israel
      • 8.6.6.1. Israel: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.6.7. Cytomegalovirus Treatment Market - South Africa
      • 8.6.7.1. South Africa: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
  • 8.7. Cytomegalovirus Treatment Market - Latin America
    • 8.7.1. Latin America: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.7.4. Cytomegalovirus Treatment Market - Mexico
      • 8.7.4.1. Mexico: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.7.5. Cytomegalovirus Treatment Market - Brazil
      • 8.7.5.1. Brazil: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)
    • 8.7.6. Cytomegalovirus Treatment Market - Argentina
      • 8.7.6.1. Argentina: Cytomegalovirus Treatment Market, by Drug, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Cytomegalovirus Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Cytomegalovirus Treatment Market, by Application, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Bayer AG
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bristol Myers Squibb
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Chimerix
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Clinigen Group
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Eli Lilly and Company
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. F. Hoffmann-La Roche Ltd
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Fresenius Kabi
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Genentech, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Gilead Sciences, Inc
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. GlaxoSmithKline plc
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Merck & Co., Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Pfizer Inc
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Takeda Pharmaceuticals
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Teva Pharmaceutical Industries Ltd.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Thermo Fisher Scientific
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제